Impact of pre-ablation weight loss on the success of catheter ablation for atrial fibrillation.
atrial fibrillation
catheter ablation
cryoballoon
pulmonary vein isolation
weight loss
Journal
Journal of cardiovascular electrophysiology
ISSN: 1540-8167
Titre abrégé: J Cardiovasc Electrophysiol
Pays: United States
ID NLM: 9010756
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
revised:
13
05
2021
received:
22
03
2021
accepted:
24
05
2021
pubmed:
1
7
2021
medline:
21
10
2021
entrez:
30
6
2021
Statut:
ppublish
Résumé
Obesity is an established risk factor for recurrent atrial fibrillation (AF) after ablation. The impact of pre-procedure weight changes on freedom from AF (FFAF) after ablation in obese and nonobese patients is unknown. A single-center retrospective cohort study of patients undergoing pulmonary vein isolation was performed. Before ablation, all candidates were encouraged to adopt healthy lifestyle habits according to American Heart Association guidelines, including weight loss, by their physician. The primary endpoint was FFAF through 1-year after completion of the 3-month blanking period. Of the 601 patients (68% male; average age 62.1 ± 10.3 years) included in analysis, 234 patients (38.9%) were obese (body mass index ≥ 30) and 315 (52.4%) had paroxysmal AF. FFAF was observed in 420 patients (69.9%) at 15 months. Percent change in weight that occurred during the year before ablation independently predicted FFAF through 15-months in all patients (adjusted odds ratio = 1.17, 95% confidence interval: 1.11-1.23). Subgroup analyses based on paroxysmal vs persistent AF, presence of obesity, and history of prior ablation were performed. Percent change in weight over the year before ablation was independently associated with FFAF in all subgroups except nonobese patients with persistent AF. Pre-ablation weight loss was associated with FFAF in both obese and nonobese patients. Further studies are needed to define the optimal approach to weight loss before AF ablation.
Identifiants
pubmed: 34191371
doi: 10.1111/jce.15141
pmc: PMC9305992
mid: NIHMS1823844
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2097-2104Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL125881
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL140061
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
J Cardiovasc Electrophysiol. 2020 May;31(5):1031-1037
pubmed: 32115794
J Am Heart Assoc. 2019 Oct 15;8(20):e012253
pubmed: 31581876
J Am Coll Cardiol. 2012 Aug 28;60(9):851-60
pubmed: 22726633
Europace. 2018 Dec 1;20(12):1929-1935
pubmed: 29912366
J Am Coll Cardiol. 2014 Dec 2;64(21):2222-31
pubmed: 25456757
J Arrhythm. 2017 Oct;33(5):369-409
pubmed: 29021841
J Am Coll Cardiol. 2015 Jul 7;66(1):1-11
pubmed: 26139051
JACC Clin Electrophysiol. 2019 Mar;5(3):306-314
pubmed: 30898232
JACC Clin Electrophysiol. 2020 Aug;6(8):958-969
pubmed: 32819531
J Cardiovasc Electrophysiol. 2018 Feb;29(2):239-245
pubmed: 29131442
J Am Heart Assoc. 2013 Mar 18;2(2):e004549
pubmed: 23537812
JAMA. 2013 Nov 20;310(19):2050-60
pubmed: 24240932
J Am Coll Cardiol. 2014 Dec 2;64(21):e1-76
pubmed: 24685669
J Interv Card Electrophysiol. 2020 Aug;58(2):209-217
pubmed: 31327104
NCHS Data Brief. 2020 Feb;(360):1-8
pubmed: 32487284
J Am Coll Cardiol. 2015 May 26;65(20):2159-69
pubmed: 25792361
Eur Heart J. 2016 May 21;37(20):1565-72
pubmed: 26371114
Circulation. 2020 Apr 21;141(16):e750-e772
pubmed: 32148086
Card Electrophysiol Clin. 2020 Jun;12(2):141-154
pubmed: 32451099
J Cardiovasc Electrophysiol. 2020 Dec;31(12):3124-3131
pubmed: 33079437
Curr Med Res Opin. 2018 Nov;34(11):1933-1943
pubmed: 29625530
Can J Cardiol. 2015 Feb;31(2):203-10
pubmed: 25661555
Circulation. 2014 Dec 2;130(23):e199-267
pubmed: 24682347
Heart Rhythm. 2013 Jan;10(1):90-100
pubmed: 23063864
Circulation. 2019 Jul 9;140(2):e125-e151
pubmed: 30686041